An2 Therapeutics (ANTX) traded down -2.47 % during a 24 hours period ending at 04:55 PM Central Europe on Monday 26th. One An2 Therapeutics stock can currently be bought for about USD 3.57 on popular exchanges. Current supply of An2 Therapeutics stocks is 37.7 mn. An2 Therapeutics has a current market capitalization of USD 134 mn and approximately USD 441.6 k worth of An2 Therapeutics was traded on exchanges in the last 24 hours. Since last month end, An2 Therapeutics has traded -27.4 % down. Simple moving average of last 200 days is at USD 4. The highest price of past 52 weeks was recorded at USD 7.19 on 08/12/2026. 52 weeks low was at USD 1 on 02/19/2026.

Here is how related stocks have performed in the past 24 hours:

  • Definitive Healthcare (DH) traded flat 0 % and now trades at USD 1.1. Definitive Healthcare has a market capitalisation of USD 156.4 mn.

  • Silver Pegasus Acquisition (SPEG) traded flat 0 % and now trades at USD 10.44. Current market capitalisation for Silver Pegasus Acquisition is USD 159.9 mn.

  • Entrada Therapeutics (TRDA) traded down -6.77 % and now trades at USD 4.7. Entrada Therapeutics has a market capitalisation of USD 159 mn.

  • Akebia Therapeutics (AKBA) traded up 0.89 % and now trades at USD 0.65. Akebia Therapeutics has a market capitalisation of USD 157.1 mn.

  • Novabridge Biosciences (NBP) traded up 3.01 % and now trades at USD 1.24. Novabridge Biosciences has a market capitalisation of USD 158.9 mn. NovaBridge Biosciences announced that the updated Phase 1b data for its CLDN18.2‑targeted bispecific antibody, givastomig, presented at the European Society for Medical Oncology Congress in Madrid, supports progression to a planned Phase 3 study. The analysis, covering 71 patients through early August 2026, provides nearly 18 months of median follow‑up for the 8 mg/kg cohort, the dose selected for registrational development. In this cohort, objective response rates approached 80 % and disease control rates exceeded 95 %, with a median response duration of just over 15 months and progression‑free survival close to 17 months. Safety data remain manageable, with no high‑grade events attributed to givastomig and only mild gastritis observed. The company has secured FDA alignment on a global registrational protocol and holds both Orphan Drug and Fast‑Track designations, underscoring a clear regulatory pathway for the program.

About An2 Therapeutics

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, United States. The company specializes in modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. Globally, they serve customers with their operations located at www.an2therapeutics.com and listed on the Nasdaq stock exchange.